Education. Evidence. Regrowth.
Prioritize knowledge. Make better choices.
Sort good studies from the bad.
Get bigger hair gains.
PhD's, resarchers, & consumer advocates.
Founder, researcher, & consumer advocate
Our team of PhD’s, researchers, & more
Discover how we conduct our research.
Have questions? Contact us.
Our library of before-after photos.
I have attached my before and afters of my progress since joining this group...
I’m convinced I’ve recovered to probably the hairline I had 3 years ago. Super stoked…
My friends actually told me, “Your hairline improved. Your hair looks thicker...
I also feel my hair has a different texture to it now…
Firstly thank you for your work in this field. I am immensely grateful that...
I just wanted to thank you for all your research, for introducing me to this method...
To be honest I am having fun with all this and I still don’t know how much...
I see a massive amount of regrowth that is all less than about 8 cm long...
150+ member experiences.
Popular treatments. But do they work?
Top-selling ingredients, quantified.
The truth about hair loss "best sellers".
Xyon Health
Strut Health
Happy Head
DS Laboratories
Advanced Trichology
Fully Vital
Xyon Health
DrFormulas
Revivogen MD
Standardized rubrics to evaluate all treatments.
Is this treatment well studied?
How much regrowth can you expect?
Is this treatment safe & sustainable?
Apps, tools, guides, freebies, & more.
100+ free articles.
Our team’s peer-reviewed studies.
Education. Evidence. Regrowth.
PhD's, resarchers, & consumer advocates.
Discover how we conduct our research.
Have questions? Contact us.
Our library of before-after photos.
Read the experiences of members
Dutasteride is a drug that lowers dihydrotestosterone (DHT) – a hormone causally linked to androgenic alopecia. Dutasteride is FDA-approved to treat benign prostatic hyperplasia, but is also prescribed off-label for hair loss in oral, topical, and mesotherapy formulations.
Dutasteride lowers DHT by inhibiting type I and II 5-alpha reductase. At daily doses of 0.5 mg and higher, dutasteride can reduce DHT by 90% and more.
Clinical studies show that dutasteride reduces more DHT and grows more hair than finasteride. Despite this, dutasteride has no increased risk versus finasteride for sexual side effects. Interestingly, topical dutasteride is well-tolerated by members here who experienced side effects on topical finasteride – with some members showing no changes to serum DHT at applications up to 6 mg weekly of topical dutasteride.
Dutasteride is a drug that lowers dihydrotestosterone (DHT) – a hormone causally linked to androgenic alopecia. Dutasteride is FDA-approved to treat benign prostatic hyperplasia, but is also prescribed off-label for hair loss in oral, topical, and mesotherapy formulations.
Dutasteride lowers DHT by inhibiting type I and II 5-alpha reductase. At daily doses of 0.5 mg and higher, dutasteride can reduce DHT by 90% and more.
Clinical studies show that dutasteride reduces more DHT and grows more hair than finasteride. Despite this, dutasteride has no increased risk versus finasteride for sexual side effects. Interestingly, topical dutasteride is well-tolerated by members here who experienced side effects on topical finasteride – with some members showing no changes to serum DHT at applications up to 6 mg weekly of topical dutasteride.
Dutasteride is a drug that lowers dihydrotestosterone (DHT) – a hormone causally linked to androgenic alopecia. Dutasteride is FDA-approved to treat benign prostatic hyperplasia, but is also prescribed off-label for hair loss in oral, topical, and mesotherapy formulations.
Dutasteride lowers DHT by inhibiting type I and II 5-alpha reductase. At daily doses of 0.5 mg and higher, dutasteride can reduce DHT by 90% and more.
Clinical studies show that dutasteride reduces more DHT and grows more hair than finasteride. Despite this, dutasteride has no increased risk versus finasteride or sexual side effects. Interestingly, topical dutasteride is well-tolerated by members here who experienced side effects on topical finasteride – with some members showing no changes to serum DHT at applications up to 6 mg weekly of topical dutasteride.
Explore the science behind hair loss and hair growth. Our in-depth articles cover topics ranging from natural remedies to pharmaceuticals to breakthroughs in hair loss science. Want to request an article topic? Contact us.
Explore the science behind hair loss and hair growth. Our in-depth articles cover topics ranging from natural remedies to pharmaceuticals to breakthroughs in hair loss science. Want to request an article topic? Contact us.
Explore the science behind hair loss and hair growth. Our in-depth articles cover topics ranging from natural remedies to pharmaceuticals to breakthroughs in hair loss science. Want to request an article topic? Contact us.
Want the latest research on Oral Dutasteride? Every quarter, our research team conducts a literature search on Oral Dutasteride to keep you up-to-date on new studies. See our search criteria & research tables below – including a summary of key findings from every single study.
Last updated: October 2024
Parameter | Inclusion Criteria | Exclusion Criteria |
---|---|---|
Patients | Patients of any age with hair loss. | Patients with no hair loss disorder. |
Intervention | Oral dutasteride as a standalone or adjunct therapy. | A study that doesn’t contain oral dutasteride either as a standalone or adjunct therapy. |
Comparator | Placebo and/or other therapies or baseline. | No comparator. |
Outcomes | Primary Endpoints of phototrichogram, investigator, and/or patient assessments. | Any study not designed to adequately test for the standalone or additive effect of oral dutasteride. |
Study Design | Prospective, observational, retrospective, and case series studies. | Literature reviews, non-human subjects, or ongoing clinical trials. |
Study | Participants | Design | Treatment | Results | Key Takeaway | Adverse Effects | Evidence Quality | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Authors (year) | Sex | Hair Loss Type | Design | Dose | Usage | Duration | Endpoints | Hair Growth Assessments and Changes in Serum/Scalp DHT | Summary | Limitations | Adverse Effects | Jadad Score |
Vano-Galvan et al (2020) | n=42 (m) Group 1: 12 Group 2: 15 Group 3: 15 | AGA | Retrospective, monocentric, descriptive study | Group 1: less than 3 0.5 mg DST capsules/week Group 2: 5 0.5 mg DST capsules/week Group 3: 7 0/5 mg DST capsules/week. | Weekly. | 52 weeks minimum. | Comparison of pre-and post-treatment with clinical images by 3 independent dermatologists using a 4-point scale. | Group 1: 4/12 patients were stable, and 8/12 patients showed mild improvement. Group 2: 11/15 patients showed mild improvement, 4/15 patients showed marked improvement. Group 3: 9/15 patients showed mild improvement, 6/15 patients showed marked improvement. | 7 capsules of 0.5 mg DST appeared to lead to the highest number of patients who showed marked improvement. | Retrospective study. | Group 2: Erectile dysfunction (1), Decreased libido (1). Group 3: Decreased libido (1). None of these side effects caused withdrawal from the study. | 1 |
Tsunemi et al (2016) | n=110 (M) | AGA | Multicenter, open-label, prospective, outpatient study. | All patients took 1 capsule of 0.5 mg DST. | Once daily. | 52 weeks. | Hair growth, hair restoration, global improvement in hair and change in AGA stage, safety assessments. | Mean target hair count: Baseline: 87.3±81.14 Week 26: 72±102.6 Week 52: 68.1±82.14 Hair Width: Week 26: 6.7 μm±4.8 Week 52: 6.5 μm±5.29 Terminal Hair Count: Week 26: 60.8±70.22 Week 52: 76.9±86.19 Investigator Assessment: Week 52: Improvement was observed in 40% of patients who were at stage III vertex at baseline, 43% of patients who were at stage IV, and 84% of patients who were at stage V. Serum DHT: Week 26: -84.9% compared to baseline Week 52: -85.4% compared to baseline. | 0.5 mg of DHT appears to exhibit good efficacy, safety, and tolerability. | High variation in results, open-label design. | Drug-related adverse events: Erectile dysfunction (11%), libido decrease (8%), Ejaculation disorder (4%), sexual dysfunction (3%), retrograde ejaculation (<1), depressed mood (<1), suicidal ideation (<1), headache (<1), sensory disturbance (<1), fatigue (<1), rash (<1), hypertension (<1). | 1 |
Stough (2007) | n=34 (17 pairs of twins) Group 1: 17 Group 2: 17 | AGA | A randomized, placebo-controlled, double-blind study. | Group 1: 0.5 mg Group 2: placebo | Once daily | 52 weeks. | Standardized clinical photographs, Hair counts, and Patient self-assessment questionnaires. | Change from Baseline - Hair Counts at 52 weeks: Week 52: Group 1: +16.5 Group 2: -3.8 Hair Growth Scores: Week 52: Group 1: 5 (slightly improved) Group 2: 4.07 (no change) | 0.5 mg DST daily appears to improve hair counts and scores over a year of treatment. | Small sample size. | Group 1: decreased libido of mild to moderate severity (2). | 3 |
Want the latest research on Topical Dutasteride? Every quarter, our research team conducts a literature search on Topical Dutasteride to keep you up-to-date on new studies. See our search criteria & research tables below – including a summary of key findings from every single study.
Last updated: October 2024
Parameter | Inclusion Criteria | Exclusion Criteria |
---|---|---|
Patients | Patients of any age with hair loss. | Patients with no hair loss disorder. |
Intervention | Topical dutasteride as a standalone or adjunct therapy. | A study that doesn’t contain topical dutasteride either as a standalone or adjunct therapy. |
Comparator | Placebo and/or other therapies or baseline. | No comparator. |
Outcomes | Primary Endpoints of phototrichogram, investigator, and/or patient or physician assessments. | None. |
Study Design | Prospective, observational, retrospective, and case series studies. | Literature reviews, non-human subjects, or ongoing clinical trials. |
Study | Participants | Design | Treatment | Results | Key Takeaway | Adverse Effects | Evidence Quality | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Authors (year) | Sex | Hair Loss Type | Design | Dose | Usage | Duration | Endpoints | Hair Growth Assessments and Changes in Serum/Scalp DHT | Summary | Limitations | Adverse Effects | Jadad Score |
Nada et al (2018) | n=30 (M) Group 1: 15 Group 2: 15 | AGA | Prospective, randomized, clinical study | Group 1: MN + topical DST (0.02%) Group 2: MN only | 13 sessions (once every week for 8 weeks, then once every two weeks for one month, then once every month for three months) | 24 weeks | Hair loss grading, phototrichoscopy (hair density, hair width, terminal/vellus hair ratio), patient self-assessment, investigator assessment, adverse effects, and hormone levels. | Change in hair density: Group 1: 27.6±62.49 Group 2: -9±30.30 (p=0.02) Change in hair width: Group 1: 0.023±0.024 Group 2: 0.0003±0.015 (p=0.003) Change in terminal/vellus ratio: Group 1: 3.10±6.17 Group 2: 0.17±1.40 (p=0.02) Patient self-assessment: Higher ‘improvement’ and ‘satisfaction’ scores in Group 1 than in Group 2. Change in serum DHT: Group 1: -22±40.60 | A combination of MN and 0.02% DST was able to significantly increase hair density and width, as well as improve the terminal/vellus ratio. Serum DHT was also reduced. Patient-self-assessment was improved however, according to the investigator assessment, there was no change in the Norwood/Hamilton scale. | Small sample size, short follow-up period. | Group 1: Pain = 86.67% (13) Headache = 13.33% (2) Itching = 33.33% (5) Group 2: Pain = 66.67% (10) | 2 |
Sanchez-Meta et al (2022) | n=34 (M) Group 1: 17 Group 2: 17 | AGA | Comparative, double-blind, randomized prospective study. | Group 1: MN + topical DST (0.01%) Group 2: MN only | 12 treatments (3 every 4 weeks), then follow-up at 16 weeks. | 16 weeks | GPA using a 4-point rating scale, photo-trichoscopy, pain assessment using VAS | GPA: Group 1: 11.8% mild, 35.3% moderate, and 52.9% marked improvement. Group 2: 47.1%, 35.3%, and 17.6%, respectively (p = 0.037). Hair diameter from baseline: dutasteride (frontal) 6µm vs 16µm, (occipital) 5µm vs 12µm (p = 0.049). Hair density from baseline: dutasteride (frontal) 5.5 vs. 26.6 hairs per cm2, (occipital) 5 vs. 12 hairs per cm2 (p = 0.045). Vellus terminal ratio: (frontal) -0.09 vs -0.38, (occipital) no data. (p = 0.045). | MN + DST produces a superior overall change in hair thickness and density compared to MN alone. | Small sample size and short treatment duration | Erythema and sensitive scalp lasting up to 36 hours affected 88.2% and 84.2% of saline and dutasteride groups, respectively. | 2 |
Want the latest research on Mesotherapy Dutasteride? Every quarter, our research team conducts a literature search on Mesotherapy Dutasteride to keep you up-to-date on new studies. See our search criteria & research tables below – including a summary of key findings from every single study.
Last updated: October 2024
Parameter | Inclusion Criteria | Exclusion Criteria |
---|---|---|
Patients | Patients of any age with hair loss. | Patients with no hair loss disorder. |
Intervention | Mesotherapy dutasteride as a standalone or adjunct therapy. | A study that doesn’t contain mesotherapy dutasteride either as a standalone or adjunct therapy. |
Comparator | Placebo and/or other therapies or baseline. | No comparator. |
Outcomes | Primary Endpoints of phototrichogram, investigator, and/or patient or physician assessments. | None. |
Study Design | Prospective, observational, retrospective, and case series studies. | Literature reviews, non-human subjects, or ongoing clinical trials. |
Study | Participants | Design | Treatment | Results | Key Takeaway | Adverse Effects | Evidence Quality | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Authors (year) | Sex | Hair Loss Type | Design | Treatment Types | Treatment Regimen | Procedure | No. of Sessions | Duration | Endpoints | Hair Growth Assessments | Summary | Limitations | Adverse Effects | Jadad Score |
Moftah et al (2021) | n=51 (F) Group 1: 26 (with FPHL + MetS) Group 2: 25 (without FPHL + MetS) | FPHL with MetS | Prospective cohort study | 0.02% DST injections | Weekly for 12 weeks, then every 8 weeks for 32 weeks. | Intradermal injection in a defined area of the vertex by 0.05 ml at 2 cm interval using a 30-gauge needle with 30° angle. | 16 | 47 weeks | Trichoscopy, Investigator assessment, patient self-assessment, evaluation of side effects | 3 months post - treatment: % of Terminal hair = Group 1: 70.86%±11.95 Group 2: 86.04%±6.17 % Vellus hair = Group 1: 29.29%±12.02 Group 2: 14.45%±5.98 Mean Hair Thickness: Group 1: 0.024 mm±0.009 Group 2: 0.033 mm±0.007 Investigator Assessment: Group 1: 0.9±0.91 (stabilization) Group 2: 1.9±0.91 (slight improvement). | MetS negatively impacted response to intradermal injection of DST for patients with FPHL. | Small sample size, short follow-up period. | None were reported in either group. | 2 |
Saceda-Corralo et al (2017) | n=6 (M = 5) (F =1) | AGA | Prospective clinical study | 0.01% DST | Every 3 months | Not reported | 3 | 24 weeks with assessments taking place 36 weeks after the last session | Serum hormone tests and trichoscopuy | Serum Hormone: No differences were observed before and after treatment. Trichoscopy: Increase in hair density and diameter observed. | DST intradermal injection may be an effective therapy for patient with AGA, even with less intensive treatment schedules. | Small sample size, No raw data given for hair counts. | No adverse effects recorded. | 1 |
Moftah et al (2013) | n= 126 (F). Group 1: 86 Group 2: 40 | FPHL | Placebo controlled, open, randomized, prospective study. | Group 1: 2 mL of 0.05% DST solution. Group 2: 2 mL of saline. | Weekly for 8 weeks, then weeks 10, 12, and 16. | Intradermal injection of vertex by 0.05 ml solution at a 1 cm interval at a 2-4 mm depth at an angle of 30-60° using a 4 mm long 30 gauge needle. | 11 | 16 weeks | GPA using a 6-point rating scale, week, hair pull (with epilated hair count), hair strand diameter, and patient self-assessment. Five patients were also given ultrastructural examinations. | GPA: improvement in 62.8% of the treatment group (30.2% mild, 15.1% excellent) (p <0.05). For the control group 17.5% of users showed mild improvement. Hair number in the hair pull test at baseline: 5.2 ± 1.2 vs 3.8 ± 1.7 at week 18 in the treatment group and 4.7 ± 1.5 in the control group (p < 0.05). Hair Diameter: 25.8 ± 7.6 µm, vs 34.6 ± 11.8 µm in the treatment group compared to 26.8 ± 3.8 µm in the control group (P < 0.05). Patient self-assessment: Improvement more significant in group 1 than group 2 (p < 0.05). Ultrastructural examination: revealed return of cuticle or repair. | DST intradermal injection was effective, tolerable, and minimally invasive treatment modality in FPHL. | Did not count the number of terminal hairs per follicular unit. | Tolerable pain in both groups (82.6% and 80% respectively). Headaches reported in 22.1% and 12% respectively (up to 1 per day). Itching in 3.5% and 0% respectively. | 3 |
Sobhy et al (2013) | n=90 (M) Group 1: 30 Group 2: 30 Group 3: 30 | AGA | Randomized clinical trial | Group 1: DST 0.05% Group 2: DST 0.05%, dexpanthenol 500 mg, biotin 20 mg, pyridoxine200 mg Group 3: 0.9% saline. | Once weekly for four weeks then once every two weeks for four weeks, then once every four weeks for 12 weeks. | Not reported | 9 | 19 weeks | Trichogram analysis, investigator assessment, patient self-assessment, semenogram, and serum DHT. | Trichogram: Results favored Group B, showing statistically significant increases in anagen hair %, hair shaft diameter and anagen/telogen ratio. Patient satisfaction: Patients in Group 1 and 2 reported high levels of satisfaction. Semenogram: Group 1: Decline in semen volume + sperm motility Group 2: Decline in sperm concentration + sperm motility. No change in sperm morphology between any of the groups. | The DST-containing mixture (Group 2) appears to exhibit the highest efficacy for hair growth, however, further studies should be completed to investigate systemic absorption. | Needs further research to examine potential systemic effects. | Semen parameter changes. | 3 |